CU-CPT9aCU-CPT9aUnit sizeCat. codeDocsPriceTLR8 inhibitor10 mg inh-cc9aTDSMSDSDATA ￥1,805.00Please contact our distributorAdd to favoriteAboutSpecificationsContentsDetailsRelated products*/Specific TLR8 inhibitorInhibition of TLR8 signaling by CU-CPT9aCU-CPT9a is a potent and selective inhibitor of Toll-like receptor 8 (TLR8) [1, 2]. Under normal conditions, the binding of a TLR8 agonist, such as R848 or ssRNA, induces two TLR8 protomers to be brought into close proximity and initiates downstream NF-κB-dependent signaling [1]. CU‑CPT9a binds to and stabilizes the TLR8 dimer in its resting state. Subsequently, the stabilization of the resting state prevents TLR8 from undergoing the necessary conformational change for activation [1]. Therefore, CU‑CPT9a prevents TLR8 activation and furthermore, antagonizes any binding of TLR8 ligands. Importantly, CU-CPT9a blocks the activation of TLR8 and the subsequent NF-κB signaling without having any effect on other TLRs, especially the closely related TLR7 [1].CU-CPT9a has been used to establish previously unknown functions of TLR8 as a dominant sensor of pyrogenic Gram‑positive bacteria (i.e. S. aureus) as well as having an important role in sensing Gram‑negative bacteria (i.e. E. coli and P. aeruginosa) [2]. Additionally, CU-CPT9a has been shown to exert potent anti-inflammatory effects in samples from patients with inflammatory diseases such as osteoarthritis (OA), rheumatoid arthritis (RA), and adult-onset Still’s disease (AOSD) [1]. Key features of CU-CPT9a:CU-CPT9a specifically inhibits TLR8.CU-CPT9a binds directly to TLR8 and blocks the conformational change needed for activation.Each lot of CU-CPT9a is highly pure (>95%) and functionally tested. References:1. Zhang, S. et al., 2018. Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat Chem Biol, 14(1): 58-64.2. Moen, S.H. et al., 2019. Human Toll-like Receptor 8 (TLR8) is an Important Sensor of Pyogenic Bacteria and Is Attenuated by Cell Surface TLR Signaling. Front Immunol, 10: 1209.Figures CU-CPT9a inhibits hTLR8 in a dose-dependent response in HEK‑Blue™ hTLR8 cells. The cells were incubated with increasing concentrations of CU-CPT9a for 3 hours. Following this, either TL8-506 (10 μg/ml), a specific TLR8 agonist, or R848 (10 μg/ml), a TLR7/TLR8 agonist, were added to the cells. After overnight incubation, activation of TLR8 (NF‑κB activity) was assessed by measuring SEAP activity in the supernatant, using QUANTI-Blue Solution™, a SEAP detection reagent. Data are shown as a percentage (%) of TLR8 activity ± SEM.Specific inhibition of human TLR8 by Cu-CPT9a. HEK‑Blue™ hTLR8, HEK-Blue™ hTLR7, and HEK-Blue™ mTLR7 cells were incubated with Cu-CPT9a (1 μM) for 3 hours. Following this, R848 (10 μg/ml), a TLR7/TLR8 agonist, was added to the cells. After overnight incubation, activation of TLR8 (NF‑κB activity) was assessed by measuring SEAP activity in the supernatant, using QUANTI-Blue™ Solution, a SEAP detection reagent. Data are shown as optical density (OD) at 630nm ± SEM. Back to the topSpecificationsCAS number: 2165340-32-7Formula: C17H15NO2 Molecular weight: 265.31 g/molSolubility: 100 mM DMSOWorking concentration:  1 - 10 μM for cell culture assaysQuality control:Purity: ≥95% (UHPLC)Specific inhibition of human TLR8 by CU-CPT9a has been confirmed using cellular assays.The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ hTLR2 and HEK-Blue™ hTLR4 cells.Back to the topContents10 mg CU-CPT9a provided as a dried powder5 ml CU-CPT9a Diluent provided as a clear solution CU-CPT9a is shipped at room temperature. Upon receipt, store CU-CPT9a at -20 °C and CU-CPT9a Diluent at 4 °C. Upon resuspension of  CU-CPT9a in DMSO, prepare aliquots and store at -20 °C. Resuspended product is stable for at least 3 months when properly stored. Avoid repeated freeze-thaw cycles.Back to the topDetailsChemical structure of CU-CPT9a: Back to the topYou may also needR848 (Resiquimod)TLR7/8 Agonist - Imidazoquinoline compoundR848 VacciGrade™TLR7/8 agonist - Imidazoquinoline compound | Th1 responseTL8-506TLR8 Agonist - Benzoazepine analogssRNA40/LyoVec™TLR8 Agonist - HIV-1 LTR-derived ssRNA / LyoVec™HEK-Blue™ hTLR8Human TLR8 / NF-κB / SEAP reporter HEK293 cellsQUANTI-Blue™Alkaline phosphatase detection medium